China Medical University & Healthcare System Shine in the “2020 BIO Asia-Taiwan”

Date:July 21, 2020

Chinese Version

The “2020 BIO Asia-Taiwan” is the first large-scale international biotech conference and exhibition in Asia. The exhibition of 2020 takes place on July 23-26 at Taipei Nangang Exhibition Center, with the theme “Finding Cures in the Crisis”.


China Medical University & Healthcare System (CMU&H) has been dedicated to the development of advanced medicine. In the 2020 BIO Asia-Taiwan exhibition, it presented the fruitful research results on treating COVID-19 by cross-disciplinary research teams integrating precision medicine, new drug development, cancer research, and cell therapy. The brilliant research achievements of CMU&H has benefited many patients and made Taiwan’s effort in epidemic prevention be seen on the world stage.


In the exhibition of 2020 BIO Asia-Taiwan, CMU&H showed its abundant teaching resources and research energy through four major topics: (1) Combating the Pandemic (2) Top Cancer Research Achievements: From MD Anderson to CMU (3) Precision Medicine: Injection for Osteoarthritis with Target Function (4) Precision Test Kit for Diagnosis of Rheumatoid Arthritis.

In addition, CMU&H also invited three cooperative companies to participate in the exhibition with their products. They are: (1) EverFoutune.AI: Medical AI 2.0 (2) Ever Supreme Bio Technology: Immune Cell and Stem Cell Technology Platform (3) Ever Young BioDimension: Organ on a Chip & Bio ink.


“Taiwan has world-class medical standard and modern technology. With its professional role and medical responsibility, CMU has taken up the responsibility for epidemic prevention. Through the cooperation with academic community and industry community, we had been developing AI medical care and had bring new values to various fields including epidemic prevention, medical treatment, and health care.” said Dr. Chang-Hai Tsai, the founder and the chairman of the Board of Trustees of CMU&H.


CMU President Mien-Chie Hung is a world famous cancer scientist. He plays an important role in leading a cross-disciplinary research team that develops cutting-edge medical research to solve medical problems. At the critical period of combating the pandemic, the research team of CMU is working hard on developing vaccines and effective treatment for COVID-19. Now the research team has integrated the university’s Chinese medicine database to screen the effective Chinese medicine protease inhibitors by using FRET method and viral protease as target. A number of potential drugs have been developed, and the relevant data is prepared to be published in the near future.


China Medical University is the first university in Taiwan that focus on both western and traditional medicine. The faculty members at CMU committed to cultivating medical talents, developing advanced biotechnology medicine, and improving the quality of medical care in Taiwan “Our goal is to become a research-oriented medical university that values both teaching and service quality. CMU is moving toward globalization through collaborations with prestigious international partners, recruiting excellent talents and research teams, and developing cutting-edge medicine. CMU aims to make contribution to the biotechnology pharmaceutical industry and economic development”, said President Mien-Chie Hung.



	Chairman Chang-Hai Tsai, President Mien-Chie Hung, and Superintendent Long-Bin Jeng

Chairman Chang-Hai Tsai, President Mien-Chie Hung, and Superintendent Long-Bin Jeng

	Scientists of CMU cross-disciplinary research team

Scientists of CMU cross-disciplinary research team